Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 88,812,664
  • Shares Outstanding, K 2,532,440
  • Annual Sales, $ 23,002 M
  • Annual Income, $ 3,499 M
  • 36-Month Beta 0.72
  • Price/Sales 4.03
  • Price/Cash Flow 11.36
  • Price/Book 5.75

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.94 +7.59%
on 12/20/17
35.92 -1.35%
on 01/05/18
+2.29 (+6.91%)
since 12/19/17
3-Month
31.99 +10.78%
on 12/06/17
35.92 -1.35%
on 01/05/18
+0.73 (+2.10%)
since 10/19/17
52-Week
26.51 +33.69%
on 01/31/17
35.92 -1.35%
on 01/05/18
+7.53 (+26.98%)
since 01/19/17

Most Recent Stories

More News
Cancer Space Update: Label Expansions, Data Readouts in Focus

This week the cancer space was abuzz with news of label expansion of Kyprolis, Lynparza and Kymriah and positive data readouts for Cabometyx and Keytruda.

AZN : 35.44 (+1.06%)
MRK : 61.28 (+0.25%)
AGN : 181.33 (+0.94%)
NVS : 86.94 (+0.61%)
EXEL : 28.00 (+0.50%)
RHHBY : 30.6900 (+0.59%)
AMGN : 189.28 (+0.90%)
BLRX : 1.09 (-1.80%)
Here's Why Nektar Stock Skyrocketed Almost 500% in a Year

Nektar's (NKTR) shares soar in a year's time on a robust pipeline including several study initiations, positive readouts and strategic collaborations.

AZN : 35.44 (+1.06%)
MRK : 61.28 (+0.25%)
AMGN : 189.28 (+0.90%)
NKTR : 71.59 (+2.04%)
Nektar Boasts Strong Pipeline, Competition Remains a Woe

Nektar (NKTR) impresses with a strong pipeline of early and late-stage candidates. The company makes a significant progress with its lead candidate, Onzeald, for advanced breast cancer in adults.

AZN : 35.44 (+1.06%)
LLY : 85.49 (-0.38%)
SHPG : 144.99 (-0.48%)
NKTR : 71.59 (+2.04%)
AstraZeneca's Lynparza Label Now Includes Breast Cancer

AstraZeneca (AZN) and Merck (MRK) announce approval of label expansion of ovarian cancer drug, Lynparza, to include HER2-/HR+ breast cancer with germline BRCA-mutation.

AZN : 35.44 (+1.06%)
MRK : 61.28 (+0.25%)
MYGN : 38.62 (+1.66%)
CLVS : 56.76 (+1.59%)
Foreign Stock Roundup: Infosys Beats; AstraZeneca's Asthma Drug Gets Approval in EU

Global markets endured a volatile week, guided by opposing factors.

AZN : 35.44 (+1.06%)
NVO : 57.79 (+2.27%)
MT : 36.87 (+0.60%)
ITUB : 14.78 (+1.51%)
INFY : 17.99 (+0.39%)
VALE : 13.36 (+0.07%)
PHG : 41.03 (+2.17%)
HMC : 36.24 (+1.06%)
US OKs 1st drug aimed at women with inherited breast cancer

U.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.

AZN.LS : 5,043.000 (+1.52%)
AZN : 35.44 (+1.06%)
LYNPARZA(R) (olaparib) Approved by US FDA in Germline BRCA-Mutated Metastatic Breast Cancer

--LYNPARZA reduced the risk of disease progression or death by 42% compared to standard of care chemotherapy

AZN : 35.44 (+1.06%)
MRK : 61.28 (+0.25%)
MYGN : 38.62 (+1.66%)
AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU

AstraZeneca's (AZN) benralizumab receives approval in Europe as maintenance treatment for severe eosinophilic asthma under the trade name Fasenra.

AZN : 35.44 (+1.06%)
TEVA : 20.70 (-0.05%)
AMGN : 189.28 (+0.90%)
GSK : 38.20 (+0.08%)
Novo Nordisk's Ozempic Gets Canadian Approval for Diabetes

Novo Nordisk (NVO) announced that Health Canada has approved Ozempic to improve glycemic control in adults with type II diabetes mellitus.

AZN : 35.44 (+1.06%)
NVO : 57.79 (+2.27%)
MRK : 61.28 (+0.25%)
SNY : 44.60 (+0.20%)
Pharma Stock Roundup: Allergan Announces Job Cuts, Pfizer Inks Deals

In a relatively slow week, Allergan's (AGN) job cut announcement remained the key highlight while Pfizer's collaboration agreements with Sangamo and Arvinas were also in focus.

MYL : 46.73 (+0.47%)
AZN : 35.44 (+1.06%)
AGN : 181.33 (+0.94%)
RHHBY : 30.6900 (+0.59%)
PFE : 36.94 (-0.14%)
GSK : 38.20 (+0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

2nd Resistance Point 35.70
1st Resistance Point 35.57
Last Price 35.44
1st Support Level 35.32
2nd Support Level 35.21

See More

52-Week High 35.92
Last Price 35.44
Fibonacci 61.8% 32.33
Fibonacci 50% 31.22
Fibonacci 38.2% 30.11
52-Week Low 26.51

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.